Cellebrite DI Ltd. $CLBT Shares Acquired by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 5.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,327,882 shares of the company’s stock after acquiring an additional 63,599 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 0.55% of Cellebrite DI worth $24,606,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Apis Capital Advisors LLC boosted its holdings in Cellebrite DI by 77.3% in the third quarter. Apis Capital Advisors LLC now owns 610,000 shares of the company’s stock valued at $11,303,000 after purchasing an additional 266,000 shares in the last quarter. Ashford Capital Management Inc. increased its stake in Cellebrite DI by 34.3% in the third quarter. Ashford Capital Management Inc. now owns 1,700,285 shares of the company’s stock valued at $31,506,000 after purchasing an additional 434,615 shares during the last quarter. Lazard Asset Management LLC raised its holdings in Cellebrite DI by 16.7% during the third quarter. Lazard Asset Management LLC now owns 508,538 shares of the company’s stock worth $9,423,000 after purchasing an additional 72,869 shares in the last quarter. Raymond James Financial Inc. raised its holdings in Cellebrite DI by 5.7% during the third quarter. Raymond James Financial Inc. now owns 1,495,885 shares of the company’s stock worth $27,719,000 after purchasing an additional 80,539 shares in the last quarter. Finally, Amundi purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth approximately $264,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Needham & Company LLC reduced their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Stock Down 0.6%

CLBT opened at $14.44 on Friday. Cellebrite DI Ltd. has a 52 week low of $11.76 and a 52 week high of $20.86. The business’s 50 day moving average is $15.27 and its two-hundred day moving average is $16.91. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of 46.58, a price-to-earnings-growth ratio of 2.21 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company’s revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 earnings per share. Equities analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.